No Data
RBC Capital Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)
Buy Rating on Jasper Therapeutics: High Hopes for Briquilimab's Clinical Trials
10-Q: Quarterly report
Analysts Are Bullish on Top Healthcare Stocks: Stereotaxis (STXS), Jasper Therapeutics (JSPR)
Jasper Therapeutics; Cash, Cash Equivalents as of March 31 Totaled $118.5M >JSPR
Jasper Therapeutics; Cash, Cash Equivalents as of March 31 Totaled $118.5M >JSPR
Express News | Jasper Therapeutics Q1 EPS USD -1.03